Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
6/1/2026, 12:00:00 AM
Positive results from the EMERALD-3 Phase III trial were presented at the ASCO 2026 meeting on 2026-06-01, showing that Imfinzi and Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in patients with unresectable liver cancer; high market impact (>=10%) expected due to significant clinical efficacy.
Korean Translation
2026년 6월 1일 ASCO 2026 학회에서 EMERALD-3 3상 임상시험의 긍정적 결과가 발표됨. 임핀지 및 임주도 병용 요법이 간암 환자의 사망 위험을 30% 감소시켰으며, 탁월한 임상적 효능에 따른 10% 이상의 높은 주가 영향이 예상됨.
Related Recent Events
Abbott Laboratories (ABT) · Earnings Release
Abbott's Q2 2026 earnings release is scheduled for July 16, 2026. Analysts forecast EPS of $1.28. Medium importance estimated as earnings typically drive >5% price movement expected.
7/16/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly cash dividend of $1.25 per share has an ex-dividend date of June 12, 2026. The dividend is scheduled to be paid on June 26, 2026.
6/12/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
New Phase 3 data for the pipeline drug CagriSema to be presented at the American Diabetes Association (ADA) Scientific Sessions on June 7, 2026, with a low price impact scheduled.
6/7/2026, 12:00:00 AM
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon Athletica is scheduled to release its financial results for the first quarter of fiscal 2026 on June 4, 2026, after the market closes. High importance is estimated as earnings releases typically result in significant price volatility. scheduled
6/4/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Other
RBC Capital analysts forecast a price target of $43.00 for Life Time Group Holdings on June 2, 2026; target increases typically suggest a low positive impact, forecasted.
6/2/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
The European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) on 2026-06-01 for the treatment of ES-SCLC; expected to have a medium market impact of approximately 5% due to expanded market access.
6/1/2026, 12:00:00 AM